Korean pharmaceutical and biotechnology companies are set to present their latest studies at the American Association for Cancer Research (AACR) Annual Meeting 2024.

The AACR meeting, established in 1907 and regarded as one of the world's top three cancer conferences alongside those of the American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO), will host over 20,000 researchers in San Diego, the U.S., from April 5-10 to share knowledge and clinical research on cancer.

Among the companies presenting, Yuhan Corp. will unveil preclinical results for two immunotherapy drugs, YH32367 (ABL105) and YH41723 (IMC202), with the former being co-developed with ABL Bio and currently in phase 1 clinical trials in Korea and Australia.

YH41723, a dual-target immunotherapy, marks its first introduction at the conference, promising innovative treatment avenues.

LegoChem BioSciences is to present preclinical results of its antibody-drug conjugate (ADC) based on dual-antibody technology, including the first-in-class candidate LCB36 targeting CD20×CD22. The company aims to reveal detailed safety and efficacy data from studies conducted on mice and primates, indicating a new frontier in ADC therapeutics.

GC Cell will discuss the effectiveness and safety of combining approved targeted therapies or immunotherapies with Immuncell-LC through real-world data analysis.

Tium Bio is set to disclose preclinical research on TU2218, a dual inhibitor targeting TGF-ß and VEGF pathways, aimed at enhancing the efficacy of existing immunotherapies like Keytruda. This research underscores the potential of combinatory treatments in maximizing cancer therapy outcomes.

Prestige Biopharma will engage with two poster presentations on its pancreatic cancer antibody drug, PBP1510, currently in phase 1/2a clinical trials across multiple countries.

The presentations will cover clinical protocols and the mechanism of its target protein, CTHRC1, in pancreatic cancer progression.

Genome & Company will share preclinical findings of their novel immunotherapy 'GENA-104' through four posters, two of which were in collaboration with AI medical firm Lunit, highlighting the synergistic potential of AI and biopharmaceuticals in advancing cancer treatment.

Y Biologics reveals its research on the anti-CD39 antibody AR062, emphasizing its role in immune suppression by converting ATP to adenosine, a key energy source for cells, offering new insights into cancer immunotherapy.

Pharos iBio will present findings on its anticancer pipeline PHI-101 and PHI-501, showcasing the in vivo efficacy of these drugs in combination therapies for leukemia and malignant melanoma treatment, respectively.